FDA’s review of MDMA for PTSD highlights study bias and safety concerns
FDA’s review of MDMA for PTSD highlights study bias and safety concerns
arstechnica.com FDA’s review of MDMA for PTSD highlights study bias and safety concerns
FDA advisors will meet June 4 to discuss and vote on the therapy's effectiveness.
cross-posted from: https://reddthat.com/post/19935197
0
comments